Open Payments

BAPTIST BEAUMONT HOSPITAL

Type
Teaching hospital
Where
Beaumont, TX
Medicare CCN
450346
Received
$83,718 in 81 records, 2024 ($11,462 general, $72,256 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment3$11,462
2024Research payment78$72,256

By company

CompanyRecordsAmountYears
Dompe Farmaceutici S.p.A.70$44,9462024
GlaxoSmithKline, LLC.8$27,3102024
AngioDynamics, Inc.1$9,8332024
Boston Scientific Corporation1$1,0452024
Fisher & Paykel Healthcare Inc1$5832024

By nature of payment

NatureRecordsAmount
Research payment78$72,256
Long term medical supply or device loan3$11,462

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31AngioDynamics, Inc.$9,833Long term medical supply or device loanIn-kind items and servicesAuryon Laser System 100-120 Vac Device, ET2024
2024-12-31Fisher & Paykel Healthcare Inc$583Long term medical supply or device loanIn-kind items and servicesFISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier2024
2024-12-02GlaxoSmithKline, LLC.$7,295Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-12-02GlaxoSmithKline, LLC.$763Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-09-11Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-09-11Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-09-11Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-09-11Dompe Farmaceutici S.p.A.$654Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-09-06GlaxoSmithKline, LLC.$3,649Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-09-06GlaxoSmithKline, LLC.$2,371Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-09-06GlaxoSmithKline, LLC.$733Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-08-13Boston Scientific Corporation$1,045Long term medical supply or device loanIn-kind items and servicesRezum Device, Rezum2024
2024-07-24Dompe Farmaceutici S.p.A.$1,307Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$1,307Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$1,279Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$1,241Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$1,089Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$1,089Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-07-24Dompe Farmaceutici S.p.A.$750Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,279Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,279Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,241Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,241Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,089Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$1,089Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$987Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$950Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$750Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-19Dompe Farmaceutici S.p.A.$116Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-06-12Dompe Farmaceutici S.p.A.$1,661Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-05-17Dompe Farmaceutici S.p.A.$1,389Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-05-17Dompe Farmaceutici S.p.A.$944Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-05-17Dompe Farmaceutici S.p.A.$944Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-05-01Dompe Farmaceutici S.p.A.$25Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-05-01Dompe Farmaceutici S.p.A.$25Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-04-10Dompe Farmaceutici S.p.A.$1,375Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,727Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,661Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,655Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,456Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,389Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,389Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,389Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-04-05Dompe Farmaceutici S.p.A.$1,279Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-04-05Dompe Farmaceutici S.p.A.$1,279Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-04-05Dompe Farmaceutici S.p.A.$944Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-27GlaxoSmithKline, LLC.$2,016Research paymentCash or cash equivalentNUCALA Biological, IMMUNOLOGYA MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT2024
2024-03-01Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-03-01Dompe Farmaceutici S.p.A.$17Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-02-01GlaxoSmithKline, LLC.$8,377Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-02-01GlaxoSmithKline, LLC.$2,102Research paymentCash or cash equivalentA PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL2024
2024-01-04Dompe Farmaceutici S.p.A.$100Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-01-04Dompe Farmaceutici S.p.A.$43Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024
2024-01-04Dompe Farmaceutici S.p.A.$43Research paymentCash or cash equivalentPhase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf2024
2024-01-04Dompe Farmaceutici S.p.A.$28Research paymentCash or cash equivalent"Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised 2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Jefferson CountyBeaumont city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Beaumont, TX, county Jefferson County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Beaumont, TX
County
Jefferson County, TX
State
Texas
Population B01003113,279253,87830,188,424
Population, 2020 census P1115,282256,52629,145,505
Median age B0100235.337.035.6
Under 18 B0100125.3%24.6%25.0%
65 and over B0100116.3%15.5%13.4%
Households B1100145,00194,80710,992,816
Foreign born B0500211.0%12.1%17.6%
Median household income B19013$56,997$60,026$78,476
Median family income B19113$71,096$75,099$94,599
Per capita income B19301$32,642$32,101$40,752
Poverty rate B1700121.2%19.5%13.8%
Unemployment rate B230256.4%6.3%5.3%
Civilian labor force B2302552,630110,89815,233,563
Mean commute (minutes) B0801320.321.226.7
Bachelor's degree or higher B1500324.9%19.7%33.8%
Housing units B2500152,439109,88412,128,515
Owner-occupied B2500355.3%62.5%62.6%
Renters B2500344.7%37.5%37.4%
Median home value B25077$166,400$169,500$283,800
Median gross rent B25064$1,121$1,117$1,403
White, not Hispanic B0300226.3%36.3%39.1%
Black B0300245.2%32.7%11.9%
Hispanic or Latino B0300220.8%24.1%39.7%
Asian B030023.8%3.8%5.5%
American Indian and Alaska Native B030020.0%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Beaumont, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.